OLP I	R. R						
FORM PTO	.1449:8 and B (m	odified PTO/S	B/08)	APPLICATION NO.:	10/679,710	ATTY. DOCKET NO.:	C1039.70074US00
INFO	1449 and B (m MATION D		1 D T	FILING DATE:	October 3, 2003	CONFIRMATION NO.	: 9983
	EMENT BY			APPLICANT:	Krieg et al.		
Sheet	1	of	1	GROUP ART UNIT:	1648	EXAMINER:	M. S. Horning

U.S. PATENT DOCUMENTS

Examiner's	Cite L	Cite U.S. Patent Document		Name of Patentee or Applicant of Cited	Date of Publication or Issue
Initials # No.	Number	Kind Code	Document	of Cited Document MM-DD-YYYY	
,			•	,	

FOREIGN PATENT DOCUMENTS

Examiner's Ci		Fore	ign Patent Docu	ment	Name of Patentee or Applicant of Cited	Date of Publication of	Translation
Initials #	No.	Office/ Country	Number	Kind Code	Document	Cited Document MM-DD-YYYY	(Y/N)

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
/MH/		Coley Pharmaceutical Group, "Coley Pharmaceutical Group Announces Pfizer's Discontinuation of Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non Small Cell Lung Cancer," Press Release (June 20, 2007)	

/Michelle Horning/	10/19/2007

DATE CONSIDERED:

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:

[#] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).





DOCKET NO.: C1039.70074US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Krieg et al.

Serial No.:

10/679,710

Confirmation No.:

9983

Filed:

October 3, 2003

For:

IMMUNOSTIMULATORY NUCLEIC ACID MOLECULES

Examiner:

Michelle S. Horning

Art Unit:

1648

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 315+ day of January, 2007.

Emily E. Zykauskas

MAIL STOP AMENDMENT

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- Information Disclosure Statement
- PTO Form 1449 with cited references
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

By:

Helen C. Lockhart, Ph.D., Reg. No.: 39,248

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

Telephone: (617) 646-8000

Docket No.: C1039.70074US00

Date: January 31, 2007

xNDDx



DOCKET NO.: C1039.70074US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

' Krieg et al.

Serial No.:

10/679,710

Confirmation No.:

9983

Filed:

October 3, 2003

For:

IMMUNOSTIMULATORY NUCLEIC ACID

MOLECULES

Examiner:

Michelle S. Horning

Art Unit:

1648

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 315t day of January, 2007.

Emily F. Lukauskas

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing of a first Office action on the merits in the above-identified case.

No fee or certification is required.

Conf. No.: 9983

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

Serial No.	Filing Date	Inventor(s)	Docket No.
09/316,199	05-21-1999	McCluskie et al.	*C1040.70006US00
09/337,584	06-21-1999	Krieg et al.	*C1039.70020US00
09/337,893	06-21-1999	Krieg	*C1039.70022US00
09/630,319	07-31-2000	Krieg et al.	*C1039.70042US00
09/669,187	09-25-2000	Krieg et al.	*C1039.70035US00
09/786,436	09-03-1999	Wagner et al.	C1041.70010US00
10/187,489	07-02-2002	Krieg et al.	C1039.70062US00
10/811,226	03-26-2004	Wagner et al.	*C1041.70005US01
11/503,377	08-11-2006	Krieg et al.	*C1039.70061US01
11/507,079	08-18-2006	Krieg et al.	*C1039.70035US04
11/526,197	09-22-2006	Krieg et al.	*C1039.70048US23
11/526,896	09-22-2006	Bratzler et al.	*C1037.70013US03
11/542,845	10-04-2006	Krieg et al.	*C1037.70048US01
11/543,314	10-04-2006	Lipford et al.	*C1041.70036US02
11/595,823	11-10-2006	Wagner et al.	*C1041.70035US01
11/598,207	11-10-2006	Krieg et al.	*C1039.70048US24
11/603,978	11-22-2006	Forsbach et al.	*C1041.70053US02
11/629,106	12-08-2006	Lipford et al.	*C1041.70027US01
11/645,106	12-22-2006	Krieg et al.	*C1039.70083US17

^{*}A copy of this reference is not provided as the Office has waived the requirement under 37 C.F.R. 1.98(a)(2)(iii) for submitting a copy of a cited U.S. patent application if it is scanned to the Image File Wrapper system and is available on Private PAIR.

Serial No.: 10/679,710 -3 - Art Unit: 1648

Conf. No.: 9983

PART III: Explanation of Non-English Language References and Remarks Concerning Other Information Cited

The following are remarks concerning the other information cited:

The instant patent application derives priority from US 6,207,646 B1, which was involved in an Interference (Interference No. 105,171). In view of the priority, Applicants have included on the attached 1449 a listing of all of the motions filed, the judgment rendered by the Board of Patent Appeals and Interferences, appeal briefs, and appeal decision, which considered the 35 U.S.C. §135(b)(1) motion dispositive. Copies of these documents were previously submitted in Serial No. 09/818,918, filed March 27, 2001, to which the instant application derives priority. If the Examiner would like any additional information on this subject, she is encouraged to contact Applicant's representative at the number listed below.

PART IV: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

- 1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
- 2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
- 3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

Serial No.: 10/679,710 - 4 - Art Unit: 1648

Conf. No.: 9983

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By:

Helen C. Lockhart, Ph.D., Reg. No. 39,248

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

Telephone: (617) 646-8000

Docket No.: C1039.70074US00

Date: January 3, 2007

xNDDx

FORM PTO-1449/A and B (modified PTO/SB/08)

STATEMENT BY APPLICANT

APPLICATION NO.: 10/679,710 ATTY. DOCKET NO.: C1039.70074US00

FILING DATE: October 3, 2003 CONFIRMATION NO.: 9983

APPLICANT: Krieg et al.

EXAMINER: Michelle S. Horning

of 17

U.S. PATENT DOCUMENTS

1648

GROUP ART UNIT:

Examiner's	Cite	U.S. Patent Do	cument	Name of Patentee or Applicant of Cited	Date of Publication or Issue
Initials #	No.	Number	Kind Code	Document	of Cited Document MM-DD-YYYY
/MH/	A1	5,594,122		Friesen	01-14-1997
1	A2	5,663,153		Hutcherson et al.	09-02-1997
	A3	5,679,647		Carson et al.	10-21-1997
	A4	5,723,335		Hutcherson et al.	03-03-1998
	A5	5,728,518		Carmichael	03-17-1998
	- A6	5,804,566		Carson et al.	09-08-1998
	A7	5,849,719		Carson et al.	12-15-1998
	A8	5,955,059		Gilchrest et al.	09-21-1999
	A9	6,086,898		DeKruyff et al.	07-11-2000 .
	A10	6,174,872	Bl	Carson et al.	01-16-2001
	All	6,194,388	B1	Krieg et al.	02-27-2001
	A12	6,207,646	B1	Krieg et al.	03-27-2001
	A13	6,214,806	B1	Krieg et al	04-10-2001 .
	A14	6,218,371	. B1	Krieg et al.	04-17-2001
	A15	6,221,882		Macfarlane	04-24-2001
	A16	6,225,292	B1	Raz et al.	05-01-2001
	A17	6,239,116	B1	Krieg et al.	05-29-2001
	A18	6,339,068	Bl	Krieg et al.	01-15-2002
	A19	6,339,630		Macfarlane	06-04-2002
	A20	6,406,705	B1	Davis et al.	06-18-2002
	A21	6,426,336	Bl	Carson et al.	07-30-2002
	A22	6,429,199	B1	Krieg et al.	08-06-2002
	A23	6,479,504		Macfarlane et al.	11-12-2002
	A24	6,498,148	B1	Raz	12-24-2002
	A25	6,514,948	B1	Raz et al.	02-04-2003
	A26	6,521,637		Macfarlane	02-18-2003
	A27	6,534,062	B1	Raz et al.	03-18-2003
	A28	6,552,006	B2	Raz et al.	04-22-2003
	A29	6,558,670	B1	Friede et al.	05-06-2003
	A30	6,562,798	B1 .	Schwartz	05-13-2003
	A31	6,589,940	B1	Raz et al.	02-04-2003
	A32	6,610,308		Haensler	08-26-2003
ماد	A33	6,610,661	BI	Carson et al.	08-26-2003

EXAMINER:	DATE CONSIDERED:
/Michelle Horning/	10/19/2007

^{*} EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ATTY. DOCKET NO.: C1039.70074US00 APPLICATION NO.: 10/679,710 FORM PTO-1449/A and B (modified PTO/SB/08) **CONFIRMATION NO.: 9983** FILING DATE: October 3, 2003 INFORMATION DISCLOSURE APPLICANT: Krieg et al. STATEMENT BY APPLICANT GROUP ART UNIT: 1648 EXAMINER: Michelle S. Horning 2 of 17 Sheet

/MH/	A34	6,613,751	B1	Raz et al.	09-02-2003
I	A35	6,653,292	Bi	Krieg et al.	11-25-2003
	A36	6,727,230	BI	Hutcherson et al.	04-27-2004
	A37	6,737,066	B1	Moss	05-18-2004
	A38	6,821,957	Bi	Krieg et al.	11-23-2004
	A39	6,835,395	Bl	Semple et al.	12-28-2004
	A40 -	6,893,821	B2	Raz et al.	05-17-2005
1	A41	6,943,240		Bauer et al.	09-13-2005
1	A42	6,949,520		Hartmann et al.	09-27-2005
	A43	6,951,845		Carson et al.	10-04-2005
	A44	7,001,890		Wagner et al.	02-26-2006
	A45	2001-0046967	Al	Van Nest et al.	11-29-2001
	A46	2002-0028784	Al	Van Nest et al.	03-07-2002
	A47	2002-0042387	Al	Raz et al.	04-11-2002
	A48	2002-0055477	Al	Van Nest et al.	05-09-2002
	A49	2002-0086839	A1	Raz et al.	07-04-2002
	A50	2002-0091097	Al	Bratzler et al.	07-11-2002
	A51	2002-0098199	A1	Van Nest et al.	07-25-2002
	A52	2002-0107212	A1	Van Nest et al.	08-08-2002
1	A53	2002-0142977	A1	Raz et al.	10-03-2002
	A54	2002-0142978	A1	Raz et al.	10-03-2002
	A55	2002-0164341	A1	Davis et al.	11-07-2002
	A56	2002-0192184	A1	Carpentier et al.	12-19-2002
	A57	2003-0022852	Al	Van Nest et al.	01-30-2003
	A58	2003-0026801	Al	Weiner et al.	02-06-2003
	A59	2003-0027782	A1	Carson et al.	02-06-2003
	A60	2003-0049266	Al	Fearon et al.	03-13-2003
	A61	2003-0050261	A1	Krieg et al.	03-13-2003
ì	A62	2003-0050268	Al	Krieg et al.	03-13-2003
	A63	2003-0059773	A1	Van Nest et al.	03-27-2003
	A64	2003-0064064	Al	Dina et al.	04-03-2003
	A65	2003-0078223	A1	Raz et al.	04-24-2003
	A66	2003-0091599	Al	Davis et al.	05-15-2003
Ŀ	A67	2003-0092663	Al	Raz et al.	05-15-2003
	A68	2003-0100527	A1	Krieg et al.	05-29-2003
	A69	2003-0109469	A1	Carson et al.	06-12-2003

EXAMINER:	DATE CONSIDERED:
/Michelle Horning/	10/19/2007

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

EODM PTC	1449/A and P (m	odifie	1 PTO/SR/08)	APPLICATION NO.:	10/679,710	ATTY. DOCKET NO.: C1039.70074US00
	M PTO-1449/A and B (modified PTO/SB/08) NFORMATION DISCLOSURE		FILING DATE:	October 3, 2003	CONFIRMATION NO.: 9983	
	EMENT BY			APPLICANT:	Krieg et al.	
				GROUP ART UNIT:	1648	EXAMINER: Michelle S. Horning
Sheet	3	of	17	GROOT ART ONT.	1040	Die divitable internet of Horizon

/MH/	A70	2003-0119773	Al	Raz et al.	06-26-2003
1	A71	2003-0125284	Al	Raz et al.	07-03-2003
	A72	2003-0129251	Al	Van Nest et al.	07-10-2003
	A73	2003-0130217	Al	Raz et al.	07-10-2003
	A74	2003-0133988	A1	Fearon et al.	07-17-2003
	A75	2003-0139364	Al	Krieg et al.	07-24-2003
	A76	2003-0143213	A1	Raz et al.	07-31-2003
	-A77	2003-0148316	Al	Lipford et al.	08-07-2003
	A78	2003-0147870	Al	Raz et al.	08-07-2003
_	A79	2003-0148976	Al	Krieg et al.	08-07-2003
İ	A80	2003-0175731	Al	Fearon et al.	09-18-2003
	A81	2003-0176373	A1	Raz et al.	09-18-2003
	A82	2003-0176389	A1	Raz et al.	09-18-2003
	A83	2003-0181406	Al	Schetter et al.	09-25-2003
	A84	2003-0186921	A1	Carson et al.	10-02-2003
	A85	2003-0191079	Al	Krieg et al.	10-09-2003
	A86	2003-0203861	Al	Carson et al.	10-30-2003
	A87	2003-0212026	Al	Krieg et al.	11-13-2003
	A88	2003-0212028	AL	Raz et al.	11-13-2003
	A89	2003-0216340	Al	Van Nest et al.	11-20-2003
	A90	2003-0224010	Al	Davis et al.	12-04-2003
	A91	2003-0225016	Al	Fearon et al.	12-04-2003
	A92	2003-0232074	Al	Lipford et al.	12-18-2003
	A93	2003-0232780	Al	Carson et al.	12-18-2003
•	A94	2003-0232856	Al	Macfarlane	12-18-2003
	A95	2004-0006010	Al	Carson et al.	01-08-2004
	A96	2004-0006034	A1	Raz et al.	01-08-2004
	A97	2004-0009942	Al	Van Nest et al.	01-15-2004
	A98	2004-0009949	Al	Krieg	01-15-2004
1	A99	2004-0030118	A1	Wagner et al.	02-12-2004
1	A100	2004-0038922	A1	Haensler et al.	02-26-2004
	A101	2004-0053880	A1	Krieg	. 03-18-2004
	A102	2004-0067902	A9	Bratzler et al.	04-08-2004 .
1	A103	2004-0067905	Al	Krieg	04-08-2004
<u> </u>	A104	2004-0087534	A1	Krieg et al.	05-06-2004
	A105	2004-0087538	Al	Krieg et al.	05-06-2004

EXAMINER:	DATE CONSIDERED:		
		•	•

^{*}EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ATTY. DOCKET NO.: C1039.70074US00 APPLICATION NO.: 10/679,710 FORM PTO-1449/A and B (modified PTO/SB/08) **CONFIRMATION NO.: 9983** FILING DATE: October 3, 2003 INFORMATION DISCLOSURE APPLICANT: Krieg et al. STATEMENT BY APPLICANT 1648 EXAMINER: Michelle S. Horning **GROUP ART UNIT:** 17 of Sheet 4

/MH/	A106	2004-0092468	Al	Schwartz et al.	05-13-2004
1	A107	2004-0092472	Al	Krieg	05-13-2004
	A108	2004-0105872	Al	Klinman et al.	06-03-2004
	A109	2004-0106568	Al	Krieg et al.	06-03-2004
	A110	2004-0131628	ΑI	Bratzler et al.	07-08-2004
	A111	2004-0132677	Al	Fearon et al.	07-08-2004
	A112	2004-0132685	Al	Krieg et al.	07-08-2004
	A113	2004-0136948	Al	Fearon et al.	07-15-2004
	A114	2004-0142469	Al	Krieg et al.	07-22-2004
	A115	2004-0143112	Á1	Krieg et al.	07-22-2004
	A116	2004-0147468	Al	Krieg et al.	07-29-2004
	A117	2004-0152649	Al	Krieg	08-05-2004
	A118	2004-0152656	Al	Krieg et al.	08-05-2004
	A119	2004-0152657	A1	Krieg et al.	08-05-2004
	A120	2004-0162258	Al	Krieg et al.	08-19-2004
	A121	2004-0162262	Al	Krieg et al.	08-19-2004
	A122	2004-0167089	Al	Krieg et al.	08-26-2004
	A 123	2004-0171150	Al	Krieg et al.	09-02-2004
	A124	2004-0171571	Al	Krieg et al.	09-02-2004
	A125	2004-0181045	Al	Krieg et al.	09-16-2004
	A126	2004-0198680	Al	Krieg	10-07-2004
	A127.	2004-0198688	Al	Krieg et al.	10-07-2004
	A128	2004-0229835	Al	Krieg et al.	11-18-2004
	A129	2004-0234512	Al	Wagner et al.	11-25-2004
	A130	2004-0235770	Al	Davis et al.	11-25-2004
	A131	2004-0235774	Al	Bratzler et al.	11-25-2004
	A132	2004-0235777	Al	Wagner et al.	11-25-2004
	A133	2004-0235778	Al	Wagner et al.	11-25-2004
	A134	2004-0247662	Al	Dow et al.	12-09-2004
	A135	2004-0248837	Al	Raz et al.	12-09-2004
	A136	2004-0266719	Al	McCluskie et al.	12-30-2004
	A137	2005-0004061	Al	Krieg et al.	01-06-2005
	A138	2005-0004062	Al	Krieg et al.	01-06-2005
	A139	2005-0004144	Al	Carson et al.	01-06-2005
	A140	2005-0009774	Al	Krieg et al.	01-13-2005
	A141	2005-0013812	Al	Dow et al.	01-20-2005

EXAMINER: DATE CONSIDERED:

/Michelle Horning/ 10/19/2007

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO	1449/A and B (m	adified	PTO/SP/08)	APPLICATION NO.:	10/679,710	ATTY. DOCKET NO.: C1039.70074US00
	•			FILING DATE:	October 3, 2003	CONFIRMATION NO.: 9983
1	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICANT:	Krieg et al.	
			GROUP ART UNIT:	1648	EXAMINER: Michelle S. Horning	
Sheet	5	of	17	O.CO. Tilet G		

/MH/	A142	2005-0031638	Al	Dalemans et al.	02-10-2005
	A143	2005-0032734	Al	Davis et al.	02-10-2005
	A144	2005-0032736	· A1	Krieg et al.	02-10-2005
	A145	2005-0037403	Al	Krieg et al.	02-17-2005
	A146	2005-0037985	Al	Krieg et al.	02-17-2005
	A147	2005-0043529	Al	Davis et al.	02-24-2005
1	A148	2005-0049215	Al	Krieg et al.	03-03-2005
	A149	2005-0049216	Al	Krieg et al.	03-03-2005
	A150	2005-0054601	Al	Wagner et al.	03-10-2005
	A151	2005-0054602	Al	Krieg et al.	03-10-2005
	A152	2005-0059619	Al	Krieg et al.	03-17-2005
Ť	A153	2005-0059625	Al	Krieg et al.	· 03-17-2005
1	A154	2005-0059626	A1	Van Nest et al.	03-17-2005
	A155	2005-0064401	Al	Olek et al.	03-24-2005
	A156	2005-0070491	Al	Krieg et al.	03-31-2005
	A157	2005-0075302	A1	Hutcherson et al.	04-07-2005
	A158	2005-0079152	A1	Bot et al.	04-14-2005
1	A159	2005-0100983	Al	Bauer et al.	05-12-2005
	A160	2005-0101554	Al	Krieg et al.	05-12-2005
	A 1.61	2005-0101557	Al	Krieg et al.	05-12-2005
	A162	2005-0119273	Al	Lipford et al.	06-02-2005
	A163	2005-0123523	Al	Krieg et al.	06-09-2005
	A164	2005-0130911	Al	Uhlmann et al.	06-16-2005
	A165	2005-0148537	Al	Krieg et al.	07-07-2005
	A166	2005-0169888	Al	Hartman et al.	08-04-2005
	A167	2005-0171047	Al	Krieg et al.	08-04-2005
	A168	2005-0181422	Al	Bauer et al.	08-18-2005
	A169	2005-0182017	Al	Krieg	08-18-2005
	A170	2005-0197314	Al	Krieg et al.	09-08-2005
	A171	2005-0215500	Al	Krieg et al.	09-29-2005
	A172	2005-0215501	Al	Lipford et al.	09-29-2005
	A173	2005-0233995	Al	Krieg et al.	10-20-2005
	A174	2005-0233999	Al	Krieg et al.	10-20-2005
	A175	2005-0239732	Al	Krieg et al.	10-27-2005
	A176	2005-0239733	A1.	Jurk et al.	10-27-2005
7/	A177	2005-0239734	A1	Uhlmann et al.	10-27-2005

EXAMINER:	DATE CONSIDERED:

^{*}EXAMINER: Initial if reference considered, whether or noticitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ATTY. DOCKET NO.: C1039.70074US00 APPLICATION NO.: 10/679,710 FORM PTO-1449/A and B (modified PTO/SB/08) October 3, 2003 **CONFIRMATION NO.: 9983** FILING DATE: INFORMATION DISCLOSURE Krieg et al. APPLICANT: STATEMENT BY APPLICANT EXAMINER: Michelle S. Horning **GROUP ART UNIT: 1648** 17 Sheet of 2005-0239736 Krieg et al. 10-27-2005 A178 /MH/ 2005-0244379 Al Krieg et al. 11-03-2005 A179 Al Krieg et al. 2005-0250726 11-10-2005 A180 Al Lipford et al. 11-17-2005 · 2005-0256073 A181 2005-0267057 A1 Krieg 12-01-2005 A182 2005-0267064 Al Krieg et al. 12-01-2005 A183 2005-0277604 A1 Krieg et al. 12-15-2005 A184 Al Krieg et al. 12-15-2005 2005-0277609 A185 Al Krieg et al. 2006-0003955 01-05-2006 A186 2006-0003962 Αl Ahluwalia et al. 01-05-2006 A187 Αl Krieg et al. 01-26-2006 2006-0019916 A188 Davis et al. 2006-0019923 A1 01-26-2006 A189 Αl Krieg et al. 03-16-2006 2006-0058251 A190 Al Krieg et al. 04-27-2006 2006-0089326 A191 05-04-2006 ΑÎ Krieg et al. 2006-0094683 A192 2006-0140875 A1 Krieg et al. 06-29-2006 A193 Αl Bratzler et al. 07-13-2006 2006-0154890 A194 Lipford et al. 08-03-2006 2006-0172966 Al A195 08-24-2006 Al Krieg et al. 2006-0188913 A196 2006-0211639 Al Bratzler et al. 09-21-2006 A197 Krieg et al. 09-21-2006 ΑI 2006-0211644 A198 Krieg et al. 10-12-2006 2006-0229271 Al A 199 Αl Uhlmann et al. 10-26-2006 2006-0241076 A200 Ahluwalia et al. 11-02-2006 Αl A201 2006-0246035 Hartmann et al. 12-21-2006 ΑI 2006-0286070 A202 2006-0287263 ΑI Davis et al. 12-21-2006 A203 Krieg et al. Αl 01-11-2007 2007-0009482 A204 Αl Krieg et al. 01-11-2007 2007-0010470 A205 FOREIGN PATENT DOCUMENTS Date of Foreign Patent Document Translation Name of Patentee or Applicant of Cited Publication of Examiner's Cite Kind Office/ Cited Document (Y/N) Document Initia's " No. Number MM-DD-YYYY Country Code New England Medical Center Hospitals, 02-08-1989 EP 0 302 758 Αl Bl Inc. 01-29-1992 EP 0 468 520 A2 Mitsui Toatsu Chemicals, Inc. B2 09-05-1991 wo 91/12811 Αĺ ISIS Pharmaceuticals Inc. B3

¥	•
EXAMINER:	DATE CONSIDERED:
	·
1	

[#] EXAMINER: Initial if reference considered, whether or noticitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ATTY. DOCKET NO.: C1039.70074US00 APPLICATION NO.: 10/679,710 FORM PTO-1449/A and B (modified PTO/SB/08) October 3, 2003 **CONFIRMATION NO.: 9983** FILING DATE: INFORMATION DISCLOSURE Krieg et al. APPLICANT: STATEMENT BY APPLICANT GROUP ART UNIT: 1648 EXAMINER: Michelle S. Horning 7 of 17 Sheet

/MH/	B4	wo	92/03456		ISIS Pharmaceuticals Inc.	03-05-1992
ı	B5	wo	94/19945	A1	ISIS Pharmaceuticals Inc.	09-15-1994
	В6	wo	97/28259	Al	The Regents of the University of California	08-07-1997
	B7	wo	98/16247	Al	The Regents of the University of California	04-23-1998
	B8	wo	98/49288	A1	Hybridon Inc.	11-05-1998
	B9	wo	98/55495	A2	Dynavax Technologies Corporation	12-10-1998
	B10	wo	99/33488	A2	SmithKline Beecham Biologicals S.A.	07-08-1999
	B11	wo	99/52549	Al	SmithKline Beecham Biologicals S.A.	10-29-1999
	B12	wo	99/62923	A2	Dynavax Technologies Corporation	12-09-1999
	B13	wo	00/20039	Al	The Regents of the University of California	04-13-2000
	B14	wo	00/21556	Al	Dynavax Technologies Corporation	04-20-2000
	B15	wo	00/62787	Al	Regents of the University of California	10-26-2000
	B16	wo	01/12223	A2	Dynavax Technologies Corporation	02-22-2001
	B17	wo	01/35991	A2	Dynavax Technologies Corporation	05-25-2001

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Exam Initial		Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		Cl	ABED et al., Interferon-gamma regulation of B lymphocyte differentiation: activation of B cells is a prerequisite for IFN-gamma-mediated inhibition of B cell differentiation. Cell Immunol. 1994 Feb;153(2):356-66.	
		C2	AGRAWAL et al., Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol Med. 2002 Mar;8(3):114-21.	
		C3-	AGRAWAL et al., Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7595-9.	
,		C4	AGRAWAL et al., Chapter 19: Pharmacokinetics and bioavailability of antisense oligonucleotides following oral and colorectal administrations in experimental animals. 1998: 525-43.	
		C5	ANITESCU et al., Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12. J Interferon Cytokine Res. 1997 Dec;17(12):781-8.	
		C6	BALLAS et al., Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol. 1996 Sep 1;157(5):1840-5.	
	- *	C7	BOGGS et al., Characterization and modulation of immune stimulation by modified oligonucleotides. Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):461-71.	
		C8	BRANDA et al., Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochem Pharmacol. 1993 May 25;45(10):2037-43.	•
		C9	BRANDA et al., Amplification of antibody production by phosphorothicate oligodeoxynucleotides. J Lab Clin Med. 1996 Sep;128(3):329-38.	

EXAMINER:	DATE CONSIDERED:	
:		

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

EODM PTO	FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICATION NO.:	10/679,710	ATTY. DOCKET NO.: C1039.70074US00
				FILING DATE:	October 3, 2003	CONFIRMATION NO.: 9983
				APPLICANT:	Krieg et al.	
				GROUP ART UNIT:	1648	EXAMINER: Michelle S. Horning
Sheet	8	of	17	GROOF ART UNIT.	1040	DAMMINER. Michelle S. Horning

/MH/ •	C10	BRAZOLOT et al., CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15553-8.	·
	Cll	BRUNNER et al., Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol. 2000 Dec 1;165(11):6278-86.	
	C12	CARPENTIER et al., Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res. 2000 Jun;6(6):2469-73.	
	C13	CARSON et al., Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J Exp Med. 1997 Nov 17;186(10):1621-2.	<u> </u>
	C14	CHACE et al., Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol. 1997 Aug;84(2):185-93.	
	C15	CHU et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med. 1997 Nov 17;186(10):1623-31.	
	C16	COSSUM et al., Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther. 1993 Dec;267(3):1181-90.	
	C17	COWDERY et al., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol. 1996 Jun 15;156(12):4570-5.	
	C18	COWSERT et al., In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts. Antimicrob Agents Chemother. 1993 Feb;37(2):171-7.	
	C19	DEML et al., Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins. Clin Chem Lab Med. 1999 Mar;37(3):199-204.	
	C20	FRANCOIS et al., Examination of the inhibitory and stimulatory effects of IFN-alpha, -beta, and - gamma on human B-cell proliferation induced by various B-cell mitogens. Clin Immunol Immunopathol. 1988 Sep;48(3):297-306.	
	C21	FULTZ et al., Transient increases in numbers of infectious cells in an HIV-infected chimpanzee following immune stimulation. AIDS Res Hum Retroviruses. 1992 Feb;8(2):313-7.	
	C22	GALLICHAN et al., Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine. 1995 Nov;13(16):1589-95.	
	C23	GARBI et al., CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol. 2004 May 15;172(10):5861-9.	
	C24	HAFNER et al., Antimetastatic effect of CpG DNA mediated by type I IFN. Cancer Res. 2001 Jul 15;61(14):5523-8.	
	C25	HALPERN et al., Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell Immunol. 1996 Jan 10;167(1):72-8.	
	C26	HASLETT et al., Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. J Infect Dis. 2000 Apr;181(4):1264-72. Epub 2000 Apr 05.	
	C27	HAVLIR et al., Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med. 1998 Oct 29;339(18):1261-8.	

EXAMINER:	DATE CONSIDERED:
	` ·

^{*}EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

EODM PTO	1449/A and B (m	nadifia	DTO/SD/09)	APPLICATION NO.:	10/679,710	ATTY. DOCKET NO.: C1039.70074US00
	·	1449/A and B (modified PTO/SB/08) FILING DATE: October 3, 2003 CONFIRMATION NO.: 99	CONFIRMATION NO.: 9983			
1	INFORMATION DISCLOSURE STATEMENT BY APPLICANT GROUP AR	APPLICANT:	Krieg et al.			
				CROUP ART INIT	1648	EVAMINED: Michelle S Horning
Sheet			17	GROUF ART UNIT.	1070	EXAMINER. MICHEL S. Horning

/MH/	C28	HINKULA et al., Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. J Virol. 1997 Jul;71(7):5528-39.	
	C29	IVERSEN et al., Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. Antisense Res Dev. 1994 Spring;4(1):43-52.	
	C30	JAKOB et al., Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol. 1998 Sep 15;161(6):3042-9.	
	C31	JIANG et al., Enhancing immunogenicity by CpG DNA. Curr Opin Mol Ther. 2003 Apr;5(2):180-5.	
	C32	JOHNSON et al., Non-specific resistance against microbial infections induced by polyribonucleotide complexes. In: Immunopharmacology of infection diseases: Vaccine adjuvants and modulators of non-specific resistance. 1987: 291-301.	
	C33	KATAOKA et al., Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of Mycobacterium bovis BCG. Jpn J Cancer Res. 1992 Mar;83(3):244-7.	
1:	C34	KATAOKA et al., Immunotherapeutic potential in guinea-pig tumor model of deoxyribonucleic acid from Mycobacterium bovis BCG complexed with poly-L-lysine and carboxymethylcellulose. Jpn J Med Sci Biol. 1990 Oct;43(5):171-82.	
	C35	KIMURA et al., Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN. J Biochem (Tokyo). 1994 Nov;116(5):991-4.	
	C36	KLINMAN et al., Immunotherapeutic applications of CpG-containing oligodeoxynucleotides. Drug News Perspect. 2000 Jun;13(5):289-96.	
	C37	KLINMAN et al., Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004 Apr;4(4):249-58.	
	C38	KLINMAN et al., Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety. Springer Semin Immunopathol. 2000;22(1-2):173-83.	
	C39	KLINMAN et al., Immune recognition of foreign DNA: a cure for bioterrorism? Immunity. 1999 Aug;11(2):123-9.	
	C40	KLINMAN et al., Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol. 1997 Apr 15;158(8):3635-9.	
	C41	KLINMAN et al., CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2879-83.	
	C42	KRIEG et al., Lymphocyte activation mediated by oligodeoxynucleotides or DNA containing novel un-methylated CpG motifs. American College of Rheumatology 58 th National Scientific Meeting. Minneapolis, Minnesota, October 22, 1994. Abstracts. Arthritis Rheum. 1994 Sep;37(9 Suppl).	
	C43	KRIEG et al., Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev. 1996 Summer;6(2):133-9.	
	C44	KRIEG et al., Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res Dev. 1995 Winter;5(4):241.	
	C45	KRIEG et al., Leukocyte stimulation by oligodeoxynucleotides, Applied Antisense Oligonucleotide Technology, 1998; 431-448.	
	C46	KRIEG, CpG DNA: a pathogenic factor in systemic lupus erythematosus? J Clin Immunol. 1995 Nov;15(6):284-92.	

V	
EXAMINER:	DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PT	O-1449/A and B (m	odified PT	O/SB/08)	APPLICATION NO.:	10/679,710	ATTY. DOCKET NO.: C1039.70074US00
	ORMATION D			FILING DATE:	October 3, 2003	CONFIRMATION NO.: 9983
1	TEMENT BY			APPLICANT:	Krieg et al.	
Sheet	10	of	17	GROUP ART UNIT:	1648	EXAMINER: Michelle S. Horning

/MH/	C47	KRIEG et al., CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995 Apr 6;374(6522):546-9.	
	C48	KRIEG et al., Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy. Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1048-52.	
	C49	KRIEG et al., The role of CpG dinucleotides in DNA vaccines. Trends Microbiol. 1998 Jan;6(1):23-7.	
	C50	KRIEG, An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. J Lab Clin Med. 1996 Aug;128(2):128-33.	
	C51	KRIEG et al., Direct immunologic activities of CpG DNA and implications for gene therapy. J Gene Med. 1999 Jan-Feb;1(1):56-63.	
	C52	KRIEG et al., Applications of immune stimulatory CpG DNA for antigen-specific and antigen-nonspecific cancer immunotherapy. Eur J Canc. 1999 Oct; 35/Suppl4:S10. Abstract #14.	
	C53	KRIEG et al., Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. Immunol Today. 2000 Oct;21(10):521-6.	
	C54	KRIEG et al., Chapter 8: Immune Stimulation by Oligonucleotides. in Antisense Research and Application. Crooke, editor. 1998; 243-62.	
ŀ	C55	KRIEG et al., A role for endogenous retroviral sequences in the regulation of lymphocyte activation. J Immunol. 1989 Oct 15;143(8):2448-51.	
	C56	KRIEG et al., Bacterial DNA or oligonucleotides containing CpG motifs protect mice from lethal L. monocytogenes challenge. 1996 Meeting on Molecular Approaches to the Control of Infectious Diseases. Cold Spring Harbor Laboratory, September 9-13, 1996: 116.	
14/1	C57	KRIEG et al., Chapter 17:Immune stimulation by oligonucleotides. in Antisense Drug Tech. 2001;1394:471-515.	
	C58	KRIEG et al., Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta. 1999 Dec 10;1489(1):107-16.	
	C59	KRIEG et al., The CpG motif: Implications for clinical immunology. BioDrugs. 1998 Nov 1;10(5):341-6.	
	C60	KRIEG, The role of CpG motifs in innate immunity. Curr Opin Immunol. 2000 Feb;12(1):35-43.	
	C61	KRIEG et al., Mechanism of action of CpG DNA. Curr Top Microbiol Immunol. 2000;247:1-21.	
	C62	KRIEG et al., Mechanisms and therapeutic applications of immune stimulatory CpG DNA. Pharmacol Ther. 1999 Nov;84(2):113-20.	
	C63	KRIEG et al., Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12631-6.	
	C64	KRIEG et al., CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol. 1998 Sep 1;161(5):2428-34.	
	C65	KRIEG et al., CpG DNA: a novel immunomodulator. Trends Microbiol. 1999 Feb;7(2):64-5.	
	C66	KRIEG, Signal transduction induced by immunostimulatory CpG DNA. Springer Semin Immunopathol. 2000;22(1-2):97-105.	
	C67	KRIEG et al., Unmethylated CpG DNA protects mice from lethal listeria monocytogenes challenge. Vaccines. 1997; 97:77-9.	
	C68	KRIEG et al., Infection. In McGraw Hill Book. 1996: 242-3.	

_ V		
EXAMINER:	DATE CONSIDERED:	
		1

^{*} EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

COR	M PTO	1449/A and B	(modified	LPTO/SB/08)	APPLICATION NO.:	10/679,710	ATTY. DOCKET NO.: C1039.70074US00
	FORM PTO-1449/A and B (modified PTO/SB/08)				FILING DATE: October 3, 2003 CONFIRMATION NO.: 9983		
1					APPLICANT:	Krieg et al.	
	 ,				GROUP ART UNIT:	1648	EXAMINER: Michelle S. Horning
She	eet	11	THE PROPERTY OF THE PROPERTY O				

/MH/	C69	KRIEG et al., Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol. 1996 Feb;4(2):73-6.	
	C70	KUBY et al., Editors, "Chapter 13: Cytokines", Immunology: Second Edition, W.H. Freeman and Company, New York. 1994. p297-322.	
	C71	KULKARNI et al., Effect of dietary nucleotides on response to bacterial infections. JPEN J Parenter Enteral Nutr. 1986 Mar-Apr;10(2):169-71.	
	C72	KURAMOTO et al., Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction. Int J Immunopharmacol. 1992 Jul;14(5):773-82.	
	C73	KURAMOTO et al., Oligonucleotide sequences required for natural killer cell activation. Jpn J Cancer Res. 1992 Nov;83(11):1128-31.	
	C74	KURAMOTO et al., In situ infiltration of natural killer-like cells induced by intradermal injection of the nucleic acid fraction from BCG. Microbiol Immunol. 1989;33(11):929-40.	
	C75	LEDERMAN et al., Polydeoxyguanine motifs in a 12-mer phosphorothioate oligodeoxynucleotide augment binding to the v3 loop of HIV-1 gp120 and potency of HIV-1 inhibition independency of G-tetrad formation. Antisense Nucleic Acid Drug Dev. 1996 Winter;6(4):281-9.	•
	C76	LEIBSON et al., Role of gamma-interferon in antibody-producing responses. Nature. 1984 Jun 28-Jul 4;309(5971):799-801.	
	C77	LETSINGER et al., Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture. Proc Natl Acad Sci U S A. 1989 Sep;86(17):6553-6.	
	C78	LETSINGER et al., Synthesis and properties of modified oligonucleotides. Nucleic Acids Symp Ser. 1991;(24):75-8.	
	C79	LIPFORD et al., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol. 1997 Sep;27(9):2340-4.	
	C80	LIPFORD et al., Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur J Immunol. 1997 Dec;27(12):3420-6.	
	C81	LIU et al., Recombinant interleukin-6 protects mice against experimental bacterial infection. Infect Immun. 1992 Oct;60(10):4402-6.	
	C82	LIU et al., CpG QDN is an effective adjuvant in immunization with tumor antigen. J Invest Med. 1997 Sept7;45(7):333A.	
	C83	LOTZ et al., Effects of recombinant human interferons on rheumatoid arthritis B lymphocytes activated by Epstein-Barr virus. J Rheumatol. 1987 Feb;14(1):42-5.	
	C84	MANCILLA-RAMIREZ et al., [Phosphatidylcholine induces an increase in the production of interleukin-6 and improves survival of rats with neonatal sepsis caused by Klebsiella pneumoniae] Gac Med Mex. 1995 Jan-Feb;131(1):14-22. Spanish. Abstract only.	Yes – Abstrac
	C85	MARDH et al., Alternaria alternata as a cause of opportunistic fungal infections in man. Scand J Infect Dis Suppl. 1978;(16):36-40.	
	C86	MATSUKURA et al., Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci U S A. 1989 Jun;86(11):4244-8.	

EXAMMER:			DATE CONSIDERED:	
Extra Vitera				
	•			•
			<i>.</i>	
		•	' <u></u>	

^{*}EXAMINER: Initial if reference considered, whether or noticitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ATTY. DOCKET NO.: C1039.70074US00 APPLICATION NO.: 10/679,710 FORM PTO-1449/A and B (modified PTO/SB/08) October 3, 2003 **CONFIRMATION NO.: 9983** FILING DATE: INFORMATION DISCLOSURE APPLICANT: Krieg et al. STATEMENT BY APPLICANT GROUP ART UNIT: 1648 EXAMINER: Michelle S. Horning 17 of Sheet 12

/MH/	C87	MESSINA et al., The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens. Cell Immunol. 1993 Mar;147(1):148-57.	
	C88	METZGER et al., Enhancement of humoral immunity by interleukin-12. Ann N Y Acad Sci. 1996 Oct 31;795:100-15.	
	C89	MICONNET et al., CpG are efficient adjuvants for specific CTL induction against tumor antigenderived peptide. J Immunol. 2002 Feb 1;168(3):1212-8.	
	C90	MOJCIK et al., Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF env causes immune effects in vivo in a sequence-specific manner. Clin Immunol Immunopathol. 1993 May;67(2):130-6.	
	C91	MOND et al., Recombinant interferon-gamma inhibits the B cell proliferative response stimulated by soluble but not by Sepharose-bound anti-immunoglobulin antibody. J Immunol. 1985 Oct;135(4):2513-7.	
	C92	MOSEMAN et al., Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol. 2004 Oct 1;173(7):4433-42.	,
	C93	MOSS et al., In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides. Vaccine. 2000 Jan 6;18(11-12):1081-7.	
	C94	PISETSKY et al., Mechanisms of autoantibody production in autoimmune MRL mice. J Exp Med. 1980 Nov 1;152(5):1302-10.	
1	C95	PISETSKY et al., The immunologic properties of DNA. J Immunol. 1996 Jan 15;156(2):421-3.	
1.	C96	PISETSKY et al., Immunological properties of bacterial DNA. Ann N Y Acad Sci. 1995 Nov 27;772:152-63.	
	C97	PISETSKY et al., Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. Life Sci. 1994;54(2):101-7.	
	C98	PISETSKY, Immunologic consequences of nucleic acid therapy. Antisense Res Dev. 1995 Fall;5(3):219-25.	
	C99	PISETSKY et al., Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides. Mol Biol Rep. 1993 Oct;18(3):217-21.	
	C100	PISETSKY, The influence of base sequence on the immunostimulatory properties of DNA. Immunol Res. 1999;19(1):35-46.	
	C101	RAZ et al., Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci U S A. 1996 May 14;93(10):5141-5.	
	C102	RAZ et al., Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and autoimmunity. ACR Poster Session C: Cytokines and Inflammatory Mediators. 1996 Oct 20; Abstract 615.	
	C103	REYNOLDS et al., Inhibition of B lymphocyte activation by interferon-gamma. J Immunol. 1987 Aug 1;139(3):767-73.	
	C104	ROMAN et al., Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med. 1997 Aug;3(8):849-54.	
	C105	SATO et al., Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science. 1996 Jul 19;273(5273):352-4.	
	C106	SATOH et al., Morphological and immunohistochemical characteristics of the heterogeneous prostate-like glands (paraurethral gland) seen in female Brown-Norway rats. Toxicol Pathol. 2001 Mar-Apr;29(2):237-41.	_

\//	·	
EXAMINER:	DATE CONSIDERED:	
		ļ
i i		

^{*} EXAMINER: Initial if reference considered, whether or noticitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ATTY. DOCKET NO.: C1039.70074US00 APPLICATION NO.: 10/679,710 FORM PTO-1449/A and B (modified PTO/SB/08) October 3, 2003 **CONFIRMATION NO.: 9983** FILING DATE: INFORMATION DISCLOSURE Krieg et al. APPLICANT: STATEMENT BY APPLICANT GROUP ART UNIT: 1648 EXAMINER: Michelle S. Horning 13 of 17 Sheet

/MH/	C107	SCHWARTZ et al., Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. J Immunol. 1999 Jul 1;163(1):224-31.	
	C108	SEDEGAH et al., Interleukin 12 induction of interferon gamma-dependent protection against malaria. Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10700-2.	
	C109	SIDMAN et al., Gamma-interferon is one of several direct B cell-maturing lymphokines. Nature. 1984 Jun 28-Jul 4;309(5971):801-4.	
	C110	SJOLANDER et al., Kinetics, localization and isotype profile of antibody responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins. Scand J Immunol. 1996 Feb;43(2):164-72.	
	C111	SONEHARA et al., Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon. J Interferon Cytokine Res. 1996 Oct;16(10):799-803.	
	C112	SPARWASSER et al., Bacterial DNA causes septic shock. Nature. 1997 Mar 27;386(6623):336-7.	
	C113	SPARWASSER et al., Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. Eur J Immunol. 1997 Jul;27(7):1671-9.	
	C114	STEIN et al., Non-antisense effects of oligodeoxynucleotides. Antisense Technology. 1997; ch11: 241-64.	
	C115	STEIN et al., Antisense oligonucleotides as therapeutic agentsis the bullet really magical? Science. 1993 Aug 20;261(5124):1004-12.	
	C116	STEIN et al., Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev. 1994 Summer;4(2):67-9.	
	C117	SUN et al. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med. 1998 Dec 21;188(12):2335-42.	
	C118	SUN et al. Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons. Springer Semin Immunopathol. 2000;22(1-2):77-84.	
	C119	TOKUNAGA et al., A synthetic single-stranded DNA, poly(dG,dC), induces interferon-alpha/beta and -gamma, augments natural killer activity, and suppresses tumor growth. Jpn J Cancer Res. 1988 Jun;79(6):682-6.	
	C120	TOKUNAGA et al., Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells. Microbiol Immunol. 1992;36(1):55-66.	
	C121	VERTHELYI et al., Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin Immunol. 2003 Oct;109(1):64-71.	•
	C122	VOLLMER et al., Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol. 2004 Jan;34(1):251-62.	
	C123	WAAG et al., Injection of inactivated phase I Coxiella burnetii increases non-specific resistance to infection and stimulates lymphokine production in mice. Ann N Y Acad Sci. 1990;590:203-14.	
	C124	WEINER et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10833-7.	
	C125	WYATT et al. Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1356-60.	

EXAMINER:	DATE CONSIDERED:
¥	

^{*}EXAMINER: Initial if reference considered, whether or notitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.:	10/679,710	ATTY. DOCKET NO.: C1039.70074US00
				FILING DATE:	October 3, 2003	CONFIRMATION NO.: 9983
1	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICANT:	Krieg et al.	
				GROUP ART UNIT:	1648	EXAMINER: Michelle S. Horning
Sheet	14	of	17	GROOF ART UNIT;	1070	EXAMINER. Monone 3. Northing

/MH/	C126	YAMAMOTO et al., Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity. Microbiol Immunol. 1994;38(10):831-6.	
	C127	YAMAMOTO et al., Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. J Immunol. 1992 Jun 15;148(12):4072-6.	
	C128	YAMAMOTO et al., [Commemorative lecture of receiving Imamura Memorial Prize. II. Mode of action of oligonucleotide fraction extracted from Mycobacterium bovis BCG] Kekkaku. 1994 Sep;69(9):571-4. Japanese.	
	C129	YAMAMOTO et al., Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. Antisense Res Dev. 1994 Summer;4(2):119-22.	
	C130	YAMAMOTO et al., Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro. Jpn J Cancer Res. 1994 Aug;85(8):775-9. Abstract Only.	
	C131	YI et al., Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. J Immunol. 1996 Dec 15;157(12):5394-402.	
	C132	YI et al., IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J Immunol. 1996 Jan 15;156(2):558-64.	
	C133	ZHAO et al., Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):495-502.	
	*C134	Patent Interference No. 105,171. Iowa Preliminary Motion 3 (for judgment based on failure to comply with 35 U.S.C. 135(b)). (Electronically filed, unsigned). June 7, 2004.	
	*C135	Patent Interference No. 105,171. Iowa Preliminary Motion 4 (for judgment of no interference in fact). (Electronically filed, unsigned). June 7, 2004.	
	*C136	Patent Interference No. 105,171. Iowa Preliminary Motion 5 (for judgment based on lack of enablement). (Electronically filed, unsigned). June 7, 2004.	
	*C137	Patent Interference No. 105,171. Iowa Preliminary Motion 6 (for judgment based on lack of adequate written description). (Electronically filed, unsigned). June 7, 2004.	
	*C138	Patent Interference No. 105,171. Iowa Preliminary Motion 7 (motion to redefine interference to designate claims as not corresponding to the Count). (Electronically filed, unsigned). June 7, 2004.	
	*C139	Patent Interference No. 105,171. Iowa Preliminary Motion 8 (contingent motion to redefine the Count). (Electronically filed, unsigned). June 7, 2004.	_
	*C140	Patent Interference No. 105,171. Iowa Preliminary Motion 9 (motion for benefit of earlier application). (Electronically filed, unsigned). June 7, 2004.	
	*C141	Patent Interference No. 105,171. Iowa Preliminary Motion 10 (contingent motion to redefine the interference by adding a continuation application). (Electronically filed, unsigned). July 2, 2004.	
	*C142	Patent Interference No. 105,171. Regents of the University of California Opposition 3 (to Iowa Preliminary Motion 3 for judgment under 35 USC 135(b)). September 9, 2004.	•
7/			

	•		 · ·
EXAMINER:		DATE CONSIDERED:	
	•		

[#] EXAMINER: Initial if reference considered, whether or notitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO)-1449/A and B (m	odifie	4 PTO/SR/08)	APPLICATION NO.:	10/679,710	ATTY. DOCKET NO.: C1039.70074US00
FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE				FILING DATE:	October 3, 2003	CONFIRMATION NO.: 9983
STATEMENT BY APPLICANT			APPLICANT:	Krieg et al.		
Sheet	16	of	17	GROUP ART UNIT:	1648	EXAMINER: Michelle S. Horning

/MH/	*C163	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 4 (for judgment based on obviousness). June 7, 2004.	
	*C164	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 5 (for judgment based on anticipation). June 7, 2004.	
	*C165	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 6 (for judgment based on inequitable conduct). June 7, 2004.	
	*C166	Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary Motion 7 (for benefit of an earlier application under 37 CFR 1.633(j)). July 2, 2004.	
	*C167	Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary Motion 8 (to add additional claims under 37 CFR 1.633(c)(2) and (i)). July 2, 2004.	
	*C168	Amended Claims for Application Number 09/265,191, filed March 10, 1999.	
	*C169	Patent Interference No. 105,171. Iowa Opposition 1 (opposition to motion to designate additional claims as corresponding to the Count) (Electronically filed, unsigned). September 9, 2004.	
	*C170	Patent Interference No. 105,171. Iowa Opposition 2 (opposition to motion for judgment based on lack of written description support and introducing new matter) (Electronically filed, unsigned). September 9, 2004.	
	*C171	Patent Interference No. 105,171. Iowa Opposition 3 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.	
	*C172	Patent Interference No. 105,171. Iowa Opposition 4 (opposition to motion for judgment based on obviousness) (Electronically filed, unsigned). September 9, 2004.	:
	*C173	Patent Interference No. 105,171. Iowa Opposition 5 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.	
	*C174	Patent Interference No. 105,171. Iowa Opposition 6 (opposition to motion for judgment based on inequitable conduct) (Electronically filed, unsigned). September 9, 2004.	
	*C175	Patent Interference No. 105,171. Iowa Opposition 7 (opposition to motion for benefit of an earlier application under 7 CFR 1.633(j)) (Electronically filed, unsigned). September 9, 2004.	
	*C176	Patent Interference No. 105,171. Iowa Opposition 8 (opposition to motion to add additional claims under 37 CFR 1.633 (2) and (i)) (Electronically filed, unsigned). September 9, 2004.	
	*C177	Patent Interference No. 105,171. Regents of the University of California Reply 1 (to Iowa's opposition to UC's motion to designate Iowa claims as corresponding to the Count). October 15, 2004.	
	*C178	Patent Interference No. 105,171. Regents of the University of California Reply 2 (to lowa's opposition to UC Preliminary Motion 2 for Judgment). October 15, 2004.	
	*C179	Patent Interference No. 105,171. Regents of the University of California Reply 3 (to Iowa's Opposition to UC Preliminary Motion 3 for Judgment). October 15, 2004.	
	*C180	Patent Interference No. 105,171. Regents of the University of California Reply 4 (to Iowa's Opposition to UC Preliminary Motion 4 for Judgment). October 15, 2004.	
	*C181	Patent Interference No. 105,171. Regents of the University of California Reply 5 (to lowa's Opposition to UC Preliminary Motion 5 for Judgment). October 15, 2004.	
	*C182	Patent Interference No. 105,171. Regents of the University of California Reply 6 (to Iowa's opposition to UC Preliminary Motion 6 for judgment). October 15, 2004.	
	*C183	Patent Interference No. 105,171. Regents of the University of California Reply 7 (to lowa's Opposition to UC Preliminary Motion 7 for Benefit). October 15, 2004.	

EXAM NER:	DATE CONSIDERED:
\bigvee	

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE				APPLICATION NO.:	10/679,710	ATTY. DOCKET NO.: C1039.70074US00
				FILING DATE:	October 3, 2003	CONFIRMATION NO.: 9983
	STATEMENT BY APPLICANT			APPLICANT:	Krieg et al.	
Sheet	15	of	17	GROUP ART UNIT:	1648	EXAMINER: Michelle S. Horning

/MH/	*C143	Patent Interference No. 105,171. Regents of the University of California Opposition 4 (to Iowa Preliminary Motion 4 for judgment of no interference in fact). September 9, 2004.	
	*C144	Patent Interference No. 105,171. Regents of the University of California Opposition 5 (to Iowa Preliminary Motion 5 for judgment that UC's claim is not enabled). September 9, 2004.	
	*C145	Patent Interference No. 105,171. Regents of the University of California Opposition 6 (to Iowa Preliminary Motion 6 for judgment based on lack of adequate written description). September 9, 2004.	
	*C146	Patent Interference No. 105,171. Regents of the University of California Opposition 7 (to lowa Preliminary Motion 7 to redefine the interference). September 9, 2004.	
	*C147	Patent Interference No. 105,171. Regents of the University of California Opposition 8 (to Iowa Preliminary Motion 8 to redefine the Count). September 9, 2004.	
	*C148	Patent Interference No. 105,171. Regents of the University of California Response 9 (to Iowa Contingent Motion 9 for benefit). September 9, 2004.	
	*C149	Patent Interference No. 105,171. Regents of the University of California Opposition 10 (to Iowa Contingent Motion 10 to redefine the interference). September 9, 2004.	
	*C150	Patent Interference No. 105,171. Regents of the University of California Opposition 11 (to Iowa Contingent Motion 11 to suppress). October 15, 2004.	
	*C151	Patent Interference No. 105,171. Iowa Reply 3 (in support of Iowa Preliminary Motion 3 for judgment under 35 U.S.C. §135(b)) (Electronically filed, unsigned). October 15, 2004.	
	*C152	Patent Interference No. 105,171. Iowa Reply 4 (in support of Iowa Preliminary Motion for judgment of no interference in fact) (Electronically filed, unsigned). October 15, 2004.	
	*C153	Patent Interference No. 105,171. Iowa Reply 5 (in support of Iowa Preliminary Motion 5 for judgment that UC's claim 205 is not enabled) (Electronically filed, unsigned). October 15, 2004.	
	*C154	Patent Interference No. 105,171. Iowa Reply 6 (in support of Iowa Preliminary Motion 6 for judgment based on lack of adequate written description) (Electronically filed, unsigned). October 15, 2004.	
	*C155	Patent Interference No. 105,171. Iowa Reply 7 (in support of Iowa Preliminary Motion 7 to redefine the interference) (Electronically filed, unsigned). October 15, 2004.	
	*C156	Patent Interference No. 105,171. Iowa Reply 8 (in support of Iowa Preliminary Motion 8 to redefine the count) (Electronically filed, unsigned). October 15, 2004.	
	*C157	Patent Interference No. 105,171. lowa Reply 10 (in support of Iowa Preliminary Motion 10 to redefine the interference) (Electronically filed, unsigned). October 15, 2004.	
	*C158	Patent Interference No. 105,171. Iowa Reply 11 (in support of Iowa Miscellaneous Motion to suppress). (Electronically filed, unsigned). October 18, 2004.	
	*C159	Patent Interference No. 105,171. Regents of the University of California Preliminary Statement. June 7, 2004.	
	*C160	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 1 (to designate additional claims of Iowa patent as corresponding to the Count). June 7, 2004.	
	*C161	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 2 (for judgment based on lack of written description support and introducing new matter). June 7, 2004.	
	*C162	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 3 (for judgment based on anticipation). June 7, 2004.	

EXAMIN	ER:	DATE CONSIDERED:
	/	

^{*}EXAMINER: Initial if reference considered, whether or noticitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ATTY. DOCKET NO.: C1039.70074US00 APPLICATION NO.: 10/679,710 FORM PTO-1449/A and B (modified PTO/SB/08) October 3, 2003 **CONFIRMATION NO.: 9983** FILING DATE: INFORMATION DISCLOSURE Krieg et al. APPLICANT: STATEMENT BY APPLICANT **GROUP ART UNIT:** 1648 EXAMINER: Michelle S. Horning 17 Sheet 17 of

/MH/	*C184	Patent Interference No. 105,171. Regents of the University of California Reply 8 (to Iowa's Opposition to UC Preliminary Motion 8 to add additional claims). October 15, 2004.	
	*C185	Patent Interference No. 105,171. Decision on Motion under 37 CFR §41.125. March 10, 2005.	
	*C186	Patent Interference No. 105,171. Judgment and Order. March 10, 2005.	
	*C187	Patent Interference No. 105,171. Regents of the University of California. Brief of Appellant. July 5, 2005.	
	*C188	Patent Interference No. 105,171. University of Iowa and Coley Pharmaceutical Group, Inc. Brief of Appellees. August 17, 2005.	
	*C189	Patent Interference No. 105,171. Regents of the University of California. Reply Brief of Appellant. September 6, 2005.	
	*C190	Patent Interference No. 105,171. Regents of the University of California. Decision of CAFC. July 17, 2006.	

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/818,918, filed March 27, 2001, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
/Michelle Horning/	10/19/2007

EXAMINER: Initial if reference considered, whether or notitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.